Chronic eosinophilic leukaemia— Not otherwise specified : Clinical features , genomic insight and therapeutic strategies
British Journal of Haematology · 2025-01 · 206 (1) · 44-60
DOI: 10.1111/bjh.19921 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 26.11.2024. Verfasst von Alessandro Costa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Medical Sciences and Public Health, Businco Hospital, University of Cagliari, Cagliari, Italy. Hauptthemen laut MEDLINE: Hypereosinophilic Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 116 Literaturangaben.
Abstract (Originalsprache)
Chronic eosinophilia leukaemia—not otherwise specified (CEL‐NOS) is a rare myeloproliferative neoplasm characterized by persistent clonal hypereosinophilia. Recent advances in genetics have refined diagnostic criteria, leading to the identification of CEL subtypes with specific cytogenetic and molecular abnormalities now classified as myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, which may benefit from targeted therapies. In contrast, CEL‐NOS lacks specific genetic drivers and intervention points to halt leukemogenesis. Molecular techniques have also enabled the definition of clonality in a considerable percentage of cases otherwise classified as idiopathic hypereosinophilic syndrome. CEL‐NOS poses a significant therapeutic challenge due to limited treatment options, poor prognosis and the risk of progression to acute leukaemia. Patients, often elderly and with comorbidities, face restricted access to transplantation, the only potentially curative treatment. Unfortunately, the prognosis remains poor even post‐transplant, with a 5‐year survival rate of only one‐third of patients. Other therapies, including steroids, cytoreductive and immunomodulatory treatments, offer limited and temporary responses with significant side effects. This review aims to consolidate current knowledge on CEL‐NOS, covering diagnostic approaches, genetic advancements and therapeutic challenges. It seeks to provide a comprehensive overview and highlight critical areas for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Unit, Department of Medical Sciences and Public Health, Businco Hospital, University of Cagliari, Cagliari, Italy.
- Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.
ORCID-Profile: Alessandro Costa, Massimo Breccia
Zitieren
APA
Costa, A., Scalzulli, E., & Breccia, M. (2025). Chronic eosinophilic leukaemia— Not otherwise specified : Clinical features , genomic insight and therapeutic strategies. British Journal of Haematology, 206(1), 44-60. https://doi.org/10.1111/bjh.19921
Vancouver
Costa A, Scalzulli E, Breccia M. Chronic eosinophilic leukaemia— Not otherwise specified : Clinical features , genomic insight and therapeutic strategies. British Journal of Haematology. 2025;206(1):44-60. doi:10.1111/bjh.19921
BibTeX
@article{Costa2025,
author = {Costa, Alessandro and Scalzulli, Emilia and Breccia, Massimo},
title = {Chronic eosinophilic leukaemia— Not otherwise specified : Clinical features , genomic insight and therapeutic strategies},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {1},
pages = {44--60},
doi = {10.1111/bjh.19921}
}
EUVIMED